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Recently, NOD-SCID IL2Rγ−/− (NSG) mice were implanted with human mesenchymal 
stromal cells (MSCs) in the presence of ceramic scaffolds or matrigel in order to mimic 
the human bone marrow (BM) microenvironment. This approach allowed the 
engraftment of leukemic samples that failed to engraft in NSG mice without humanized 
niches and resulted in a better preservation of leukemic stem cell self-renewal 
properties [1-3]. To further improve our humanized niche scaffold model, we genetically 
engineered  human MSCs to secrete human IL-3 and TPO. In vitro, these IL-3 and 
TPO-producing MSCs were superior in expanding human cord blood (CB) CD34+ 
hematopoietic stem/progenitor cells. MLL-AF9-transduced CB CD34+ cells could 
efficiently be transformed along myeloid or lymphoid lineages on IL-3 and TPO-
producing MSCs. In vivo, these genetically engineered MSCs maintained their ability to 
differentiate into bone, adipocytes and various other stromal components. Upon 
transplantation of MLL-AF9-transduced cord blood CD34+ cells both AML and ALL 
developed in engineered scaffolds, whereby a significantly higher percentage of myeloid 
clones was observed in the mouse compartments compared to previous models. 
Engraftment of primary AML, B-ALL and biphenotypic acute leukemia (BAL) patient 
samples was also evaluated and all patient samples could efficiently engraft, whereby 
the myeloid compartment of the BAL samples was better preserved in the human 
cytokine scaffold model. In conclusion, we show that we can genetically engineer the 
ectopic human BM microenvironment in our humanized scaffold xenograft model. This 
approach will be useful to functionally study the importance of niche factors for normal 





 Human IL-3- and TPO-expressing MSCs support expansion of human CD34+ 
cells. 
 Genetically engineered MSCs are capable to form bone and stromal components 
in vivo. 





















Over the past decades, mouse xenograft models have significantly contributed to a 
better understanding of normal and malignant human hematopoiesis. The generation of 
immunodeficient mouse strains like the NOD-SCID IL2Rγ−/− (NSG) allowed researchers 
to functionally define human hematopoietic stem cells (HSCs) and their malignant 
counterpart [4-6]. These models also served as preclinical models for drug testing [7].  
Even though different subtypes of primary human acute myeloid leukemia (AML) 
samples can expand in these models, major limitations still exist as well. For 30-40% of 
AML samples engraftment remains challenging, especially for the favorable and 
intermediate risk groups [8-10]. This might be explained by the influence of the murine 
microenvironment and the absence of species-specific human factors. NOD-SCID and 
NSG transgenic mice expressing human factors such stem cell factor (SCF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), Interleukin-3 (IL-3), and 
thrombopoietin (TPO) have been developed and allowed an increase in the 
engraftability rate of primary AML samples [11-14]. Furthermore, the expression of 
human SCF, GM-CSF and IL-3 allowed AML development upon transplantation of cord 
blood (CB) CD34+ cells expressing the MLL-AF9 oncogene [15]. More recently, a series 
of additional models have been developed [16-22]. For instance, MISTRG mice were 
developed whereby human macrophage colony-stimulating factor (M-CSF), IL-3, GM-
CSF and TPO were knocked-in in their respective mouse loci, together with a BAC-
transgene encoding for human SIRP, supporting the development and function of 
innate immune cells in vivo [16]. 
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Yet, in these human cytokine mice essential human niche-specific factors might still be 
lacking. Also, the interaction of hematopoietic cells with specific human niche 
components (such as adipocytes, osteoblast or endothelial cells) might be critically 
important to allow homing and long-term self-renewal of HSCs. In order to reconstruct a 
human bone marrow (BM) microenvironment in immunodeficient mice, we recently 
developed an approach whereby ceramic scaffolds coated with human mesenchymal 
stromal cells (MSCs) were implanted subcutaneously in NSG mice [1,3]. We observed 
that CB CD34+ cells expressing BCR-ABL or MLL-AF9 could efficiently induce both 
AML and acute lymphoblastic leukemia (ALL) in these human BM scaffold-based 
xenografts (huBM-sc). Furthermore, a large cohort of patient samples covering all 
important genetic and risk subgroups successfully engrafted in this model, whereby 
stem cell self-renewal properties were better maintained as determined by serial 
transplantation assays and genome-wide transcriptome studies.  
Although the presence of an ectopic human BM niche presents clear advantages 
compared to normal NSG mice, some key issues still remain. For example, there are a 
number of growth factors that are not produced by MSCs, including TPO and IL-3. Here, 
we investigated whether we could genetically engineer MSCs to produce such factors 
and evaluated these modified MSCs in vitro and in vivo in humanized scaffold xenograft 
models. We engineered MSCs to overexpress IL-3 and TPO (henceforth referred to as 
cyto-MSCs) that efficiently supported expansion of human CD34+ stem/progenitor cells 
in vitro. Furthermore, these cyto-MSCs were functionally capable to form bone, 
adipocytes and various other stromal components in vivo and efficiently supported 
growth of AML, B-cell ALL (B-ALL) and biphenotypic patient samples (BAL). Lastly, we 
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found that the presence of IL-3 and TPO impacts on the lymphoid versus myeloid output 
in a CB MLL-AF9 in vivo model.  
 
Material and Methods 
Humanized scaffold niche xenograft model 
The ectopic bone model was established as described previously [1,3,23]. Briefly, four 
hybrid scaffolds consisting of three 2–3 mm biphasic calcium phosphate particles 
loaded with human MSCs and/or IL-3- and/or TPO-expressing MSCs were implanted 
subcutaneously into 6 to 8 weeks old  female NOD.Cγ-Prkdcscid Il2rγtm1Wjl/SzJ (NSG) 
mice. Six to eight weeks after scaffold implantation, different cell doses (patient samples 
or CB models) ranging from 0.9×105 to 4×106 were directly injected into the scaffolds 
during primary and secondary transplantations as indicated in the text. Human CD45 
engraftment was analysed by timely sub-mandibular bleeding procedures. Cells isolated 
from patient #1 were enriched for CD34 as previously described [24,25]. Cells isolated 
from patient #2 and #3 were CD3 depleted as previously described [1]. 
 
MS5 and MSC co-cultures  
CB CD34+ cells were grown in myeloid Gartner’s without the ectopic addition of 
cytokines. CB MLL-AF9 cells were grown under myeloid restricted and lymphoid 
permissive conditions. More detailed information can be found in the supplementary 
methods. 
 




Characterization of IL-3 and TPO expressing MSCs in vitro and in vivo 
We recently reported a human niche xenograft model in which MSCs are coated on 
scaffolds that are subcutaneously implanted in mice to generate humanized bone 
marrow niches [1,3,23]. Here, we wished to evaluate whether genetically engineered 
MSCs can be used in this model and provide tools to perform gene-function analyses to 
study the importance of niche factors for normal and malignant human hematopoiesis.  
Transcriptome studies of primary MSCs revealed that a variety of cytokines and growth 
factors  are produced, but some critically important cytokines such IL-3 and TPO are not 
(Fig. 1A, Supplemental Fig. 1A) [26] and our own unpublished MSC transcriptome 
studies (data not shown, submitted) confirmed these findings. We transduced primary 
human MSCs with lentiviral vectors expressing human IL-3 or TPO (Fig. 1B) and tNGFR 
positive cells were sorted, stored and used for further experiments (Supplemental Fig. 
1B). Conditioned supernatant (spnt) of cyto-MSC, mixed with normal MSCs in a range 
of 1-20%, was used to stimulate the IL-3 and TPO dependent MO-7e cell line for 15 
min, after which lysates were analysed for activated STAT5. As controls, cells were 
stimulated with 1-5 ng/ml IL-3 or TPO as indicated (Fig. 1C). Stimulation with as little as 
1% of IL-3 conditioned medium and 5% of TPO conditioned medium induced STAT5 
phosphorylation to comparable levels as stimulation with 1 ng/ml of these cytokines, 
suggesting that the concentration in conditioned media ranged from 10-50 pg/ml. 
Similarly, MS5 lines were generated that produced IL-3 or TPO (cyto-MS5). 
Next, stromal co-cultures were performed to functionally evaluate genetically 
engineered MSCs and MS5 murine bone marrow stromal cells. Empty vector (EV)-
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transduced or non-transduced control stromal cells were mixed with cytokine-producing 
stromal cells at various ratios. While the presence of IL-3 led to increased proliferation 
along the myeloid lineage, secretion of TPO resulted in the expansion and maintenance 
of a more immature phenotype as read out by the percentage and absolute cell counts 
of CD34+ cells, progenitor activity in CFC assays of cells taken at day 7, 14 and 28 from 
stromal co-cultures, and morphological analysis by cytospins and MGG staining (Fig. 
1D-H, Supplemental Fig. 1C-G). In particular the combination of IL-3- and TPO-
producing stroma was most efficient in expanding immature CD34+ progenitor cells (Fig. 
1D-H, Supplemental Fig. 1C-G). Importantly, cyto-MSCs were still capable to 
differentiate and form bone in vivo and HE staining indicated that a normal morphology 
of the scaffolds was obtained including the presence of adipocytes, various stromal 
components and blood vessels  (Fig.1I, Supplemental Fig. 2B ). Expression of IL-3 and 







Figure 1, Characterization of IL-3 and TPO expressing MSCs in vitro and in vivo  
A) MSC gene expression profile of selected growth factors and cytokines (GO: 
secreted). B) Schematic representation of the two lenti-viral vectors carrying IL-3 and 
THPO. C) Western blot on M-O7e whole-cell lysate showing the activation of pSTAT5 
upon the manual addition of IL-3 and/or TPO, the supernatant of MSCs or a mixture of 
cyto-MSCs with normal MSCs in different ratios. D) Growth curve of CD34+ CB isolated 
cells co-cultured with cyto-MS5 mixed in different ratios with normal MS5. MS5 EV 
transduced cells were used as control E) CD34+ cumulative count of the CB co-culture 
with MS5 at day 14. F) CFC-analysis, cumulative colony count (technical triplicate, 
±s.d.) from the CB co-culture with MS5 at day 14. G) Growth curve of CD34+ CB 
isolated cells co-cultured with cyto-MSCs mixed in different ratios with normal MSCs. H) 
MGG staining of the CB co-culture with MSCs at day 18. I) H&E staining of huBM-sc 
coated with different ratio of normal MSCs, IL-3- or  TPO-expressing MSCs or a mixture 
of cyto-MSCs and normal MSCs after 6 weeks in vivo. J) IHC staining of IL-3 and 
tNGFR of cyto-MSCs after 6 weeks in vivo. * p ≤0.05, ** p ≤0.01, *** p ≤0.001,  paired 
Student t test.  
 
Leukemic cells engraft in human cytokine producing bone marrow scaffolds and 
recapitulate patient phenotype 
Next, engraftment of primary human acute leukemic cells upon direct injection in the 
scaffolds was evaluated. Scaffolds were coated with 60% normal MSCs, 20% IL-3- and 
20% TPO-expressing MCSs (cytoBM-sc), or only with normal MSCs  as published 
previously (huBM-sc) [1]. Three different patient samples were investigated, including 
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an AML, a B-ALL and a BAL sample (Supplemental Table 1).  Leukemic CD34+ cells 
were injected between 6-8 weeks after subcutaneous implantation of the ectopic 
engineered BM niches. Efficient engraftment was observed for all leukemia samples in 
both the huBM-sc or cytoBM-sc models with comparable kinetics (Fig. 2A). The FACS 
immunophenotype of leukemic cells grown in scaffolds was compared to that of the 
original patient sample. AML patient #1 presented with a FLT3-ITD and an NPM-MLF1 
fusion at diagnosis, with 54% CD34+ cells, 79% CD33+ and 2% CD19+ cells. Leukemia 
developed in both the huBM-sc or cytoBM-sc models with palpable tumors originating 
from the scaffolds and infiltration of human CD45+ cells in the mouse compartments 
such BM, spleen and liver was observed as well. For this sample, the 
immunophenotype of the original patient sample was well preserved in both the normal 
and cytokine humanized niches (Fig. 2B). B-ALL patient #2 contained an MLL-AF4 
translocation with 99% CD19+  cells at diagnosis. For this sample, CD34-positivity of 
engrafting cells was better preserved in the cytoBM-sc model compared to the huBM-sc 
(Fig. 2A) and murine niche environment (data not shown). Lastly, we analysed patient 
#3 who presented a BAL with complex karyotype (Supplemental Table 1). Overall, cells 
retrieved from the cytoBM-sc displayed an immunophenotype that or more closely 
resembled the phenotype of the patient at diagnosis, in particular with regard to 




Figure 2, Leukemic cells engraft in cytoBM-sc and recapitulate patients 
phenotype A) Immunophenotype of 3 patients; de novo (after thawing), cells retrieved 
from human niches of huBM-sc NSG and cytoBM-sc NSG models. B-C) FACS analyses 
comparing immunophenotype of patient #1 (B) and patient #3 (C) de novo, in huBM-sc 
and cytoBM-sc. 
 
CB MLL–AF9 cells can transform along myeloid and lymphoid lineages on cyto-
MSC co-cultures. 
CB CD34+ cells transduced with MLL-AF9 can be transformed along the myeloid or 
lymphoid lineage depending on extrinsic cues [15,27]. We have previously shown that 
while in the normal NSG xenograft model MLL-AF9-induced transformation in vivo is 
heavily lymphoid biased, more myeloid transformation is observed in the humanized 
niche scaffold model [3,27]. Nevertheless, since in particular IL-3 was shown to be 
important for MLL-AF9 induced human AML in xenografts, and not produced by our 
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MSCs (Fig. 1A), we investigated the leukemic transformation potential of MLL-AF9 
transduced CB CD34+ cells in our cytoBM-sc model. 
To study this, we first cultured MLL-AF9-transduced CB cells in vitro on MSCs or a 
mixture of cyto-MSCs and MSCs supplemented with cytokines under myeloid-restricted 
or lymphoid permissive conditions. Rapid transformation was observed under all growth 
conditions (Fig. 3A). We did not observe any differences in growth between the myeloid-
restricted culture conditions and all cells remained CD33+ under both conditions (Fig. 
3A-B). Under lymphoid-permissive conditions CB MLL-AF9 cells expanded faster on 
MSCs with lymphoid cytokines compared to the cyto-MSCs (Fig. 3A). CB MLL-AF9 cells 
underwent full lymphoid transformation on MSCs with the addition of lymphoid 
cytokines, whereas in the cyto-MSCs grown under lymphoid-permissive conditions both 
lymphoid and myeloid clones were expanding (Fig. 3C). A typical feature of MLL-AF9 
transformed cells is the formation of large cobblestone areas as was observed in both 
the normal MSC as well as the cyto-MSC co-cultures (Fig. 3D). These data indicate that 
both MLL-AF9-induced myeloid as well as lymphoid transformation can be achieved in 
vitro on cyto-MSCs, whereby transformation appears to be more balanced towards the 











Figure 3, Cyto-MSC co-cultures with CB MLL–AF9 cells allow immortalization 
along the myeloid and lymphoid lineage 
A)  Total cumulative expansion of CB MLL-AF9 cells is shown. Arrow indicates when 
the cells were replated on fresh stroma. B-C)  CD33 and CD19 expression in 
suspension cells for the myeloid co-cultures (B) and lymphoid co-cultures (C) at multiple 





Increased frequency of MLL-AF9-induced myeloid leukemia in cytoBM-sc 
implanted mice  
We evaluated the in vivo MLL-AF9-driven leukemogenesis upon direct injection into 
cytoBM-sc NSG mice and compared that to our previously published models 
(intravenously (IV) injected NSG mice and scaffold injected (ISC) huBM-sc) (Fig. 4A). In  
cytoBM-sc mice (n=11), 3 out of 4 implanted scaffolds were injected with 3x105 
unsorted CB transduced MLL-AF9 cells, comparable to cell numbers that were injected 
into previously published IV or huBM-sc models. The transduction efficiency at the day 
of injection was approximately 15% (data not shown). All mice developed a fatal 
leukemia in 20-52 weeks, with a significantly longer latency compared to the previously 
used models (IV NSG vs cytoBM-sc: p=0.017, huBM-sc vs cytoBM-sc: p=0.046). 
Unexpectedly, out of the 33 injected scaffolds only 8 scaffolds developed palpable 
tumors (24%), while in the huBM-sc model this percentage was 79% (Fig. 4B). 
Nevertheless, in all the injected cytoBM-sc that did not develop tumors, we could 
confirm the presence of human cells by IHC staining for CD45+ (Supplemental Fig. 2A), 
of which a representative example is shown for mouse #5 cytoBM-sc1 (Fig. 4C), 
confirming that human cells were injected initially. The scaffold that did develop a tumor 
in mouse #5 (cytoBM-sc3) was analysed by IHC staining confirming positivity  for CD45, 
CD33 and IL-3 (Fig. 4C). Overall, the frequency of AML, B-ALL and mixed AML/B-ALL 
cells within the scaffolds was comparable between huBM-sc and cytoBM-sc models 
(Fig. 4D).  
We hypothesize that the lower rate of tumors formed on the scaffolds of cytoBM-sc mice 
might possibly be attributed to potentially high levels of exogenous IL-3 and TPO that 
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would induce differentiation or loss of long-term self-renewal properties. As confirmed 
by IHC staining for the mouse endothelial marker CD31 and VwF, cytoBM-sc were well 
vascularized, allowing leukemic clones to migrate from the site of injection to mouse 
compartments (PB, BM, spleen, liver) (Supplemental Fig. 2B). In fact, all mice 
developed an enlarged spleen, with an average weight of 0.82 ± 0.31 g (Supplemental 
Fig. 2C). In contrast to our previous IV and huBM-sc models, differences in the leukemic 
phenotypes were observed in the mouse compartments. CD33+/CD19- AML cells were 
detected in the PB, BM, spleen and liver of mouse #10 (Fig. 4D-E and Supplemental 
Fig. 2A). Even though this was only one example, such exclusively myeloid cells in PB, 
spleen, liver or BM had never been observed in any of our previous models (Fig. 4D, 
[3,27]). Furthermore, 20% of the mice displayed mixed B-ALL/AML clones in the spleen 
or liver, again a feature that was never observed in previous studies (Fig. 4D-E [3,27]). 
In the murine BM niche, the mixed B-ALL/AML frequency was in line with what was 
observed in the previous models (Fig. 4D-E). MGG staining was performed on tissues 
to confirm the myeloid and/or lymphoid cells and a representative example of mouse #1 
with mixed B-ALL/AML is shown (Fig. 4F).  
Although MSCs are not known to migrate efficiently from one organ to another, we 
questioned whether some MSCs might have migrated to the liver in the mouse that 
displayed exclusively AML cells (mouse #10). While we could detect the presence of 
CD45-expressing cells and IL-3, indicating engraftment of human cells as well as the 
presence of human IL-3, no tNGFR positive cells were detected (Fig. 4G), providing no 
evidence for the migration of MSCs to the liver. Instead, tNGFR positive cells were 
detected in the scaffolds (Fig. 1J). Overall, these data indicate that CB MLL-AF9 cells 
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can engraft in the cytoBM-sc model albeit with longer latency and lower frequency, 
while in the organs of these mice the balance in lineage output is shifted somewhat 



















Figure 4, Increased frequency of MLL-AF9-induced myeloid leukemia in cytoBM-
sc implanted mice 
A) Schematic representation of the different models injected with CB MLL-AF9 cells: IV 
injected NSG mice, ISC injected huBM-sc and ISC injected cytoBM-sc. Kaplan–Meier 
survival curves of CB MLL-AF9-injected mice, displaying the differences in kinetics of 
leukemia development. B) Percentage of tumor formation in injected scaffolds in huBM-
sc and cytoBM-sc. C) Picture depicting tumor initiated on scaffold 3 from mouse #5, with 
IHC for CD45, CD33 and IL-3 staining for scaffold 3 and HE and CD45 IHC staining of 
scaffold 1, that did not develop a solid tumor but displayed human cell engraftment. D) 
Frequencies of leukemic phenotypes observed in three different experimental set ups: 
IV injected NSG mice, ISC injected huBM-sc and ISC injected cytoBM-sc. E) FACS 
analyses of CD45+MLL-AF9+ cells from BM, liver and scaffold of ISC injected cytoBM-
sc mice displaying different leukemic phenotypes. F) MGG staining of B-ALL/AML MLL-
AF9 cells from BM, liver, and huBM-sc (mouse#5), 40x magnification. G) IHC for  CD45, 
CD33, IL-3 and tNGFR on liver sections from mouse #10. 
 
Lymphoid clones outcompete myeloid clones in secondary transplantation  
In our previously published studies using the IV NSG and huBM-sc models, CB MLL-
AF9 B-ALL cells could readily engraft in secondary recipients [3,27], while secondary 
engraftment of myeloid CD33+ clones was not achieved. For example, in an IV model in 
which we observed a mixed AML and B-ALL phenotype, we sorted CD33+/CD19- and 
CD19+/CD33- populations and transplanted them IV into secondary mice without 
scaffolds. While the CD19+/CD33- clones readily induced secondary B-ALL within 8 
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weeks after transplantation, the CD33+/CD19- clones engrafted with much slower 
kinetics (Supplemental Fig. 3A). At early phases CD33+/CD19- myeloid cells were still 
observed in the PB of these mice, however, lymphoid CD19+/CD33- clones appeared as 
well, became more dominant over time, and at the time of sacrifice at week 16 the mice 
succumbed of B-ALL and not AML (Supplemental Fig. 3A). LM-PCRs indicated that a 
minor fraction of lymphoid CD19+/CD33- B-ALL cells contaminated the myeloid 
CD33+/CD19- sorted population and it was exactly this population that generated the B-
ALL (Supplemental Fig. 3B). These data clearly highlight the lymphoid bias of routinely 
used NSG xenograft mouse models. 
We evaluated the self-renewal potential of CB MLL-AF9 AML cells generated in 
cytoBM-sc mice. We sorted GFP+/CD45+/CD33+ cells from BM, spleen, liver and 
scaffold 1 of mouse #1 and scaffold 3 of mouse #5 (Fig. 5A, Supplemental Fig. 2A).  
1.1x105 cells from BM, spleen and liver were injected per scaffold, and in total 2 
scaffolds were injected, while 0.9x105 cells from scaffold of mouse #1 and #5 were 
injected in a single scaffold of secondary cytoBM-sc mice. Secondary leukemic 
engraftment was observed only in the mouse injected with AML cells derived from BM. 
Tumor formation was observed in one of the two injected scaffolds and infiltration of CB 
MLL-AF9-positive cells was also observed in the BM, spleen and liver. Despite the fact 
that the injected cells were sorted for the myeloid marker CD33+, the secondary mouse 
developed CD19+ B-ALL. As previously observed, this may be explained by a small 
contamination of CD19+ cells during the sorting procedure (data not shown). One 
secondary mouse transplanted with AML cells derived from spleen died during the 
course of the experiment and the remaining 3 mice were sacrificed 45 weeks after 
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injection without signs of disease. These results indicate that despite the presence of an 
engineered human niche microenvironment providing IL-3 and TPO, MLL-AF9-induced 











Figure 5 Lymphoid clones outcompete myeloid clones in secondary 
transplantation  
A) FACS analyses of CB MLL-AF9 cells from BM, liver, spleen and huBM-sc of ISC 
injected cytoBM-sc (mouse #1) and huBM-sc (mouse #5). Red boxes indicate the 
sorted cells injected in secondary recipients. B) FACS analyses of MLL-AF9 cells from 
BM ISC injected secondary cytoBM-sc (mouse #1.1).C) H&E staining of engrafted 




In order to improve the in vivo xenograft modelling of human hematological 
malignancies, several laboratories have begun to build humanized microenvironments 
in xenograft mice by making use of human mesenchymal stromal cells in order to 
provide better niches in which leukemic cells can engraft [1-3,23,28-31]. In this study, 
we aimed to further develop our previously described huBM-sc model [1,3,23]using 
human MSCs that we genetically engineered to express cytokines that were not 
expressed in these cells. We engineered MSCs stably expressing human IL-3 or human 
TPO, and tested these functionally. In vitro, these IL-3 and TPO-producing MSCs were 
superior in expanding human cord blood (CB) CD34+ hematopoietic stem/progenitor 
cells. Furthermore, MLL-AF9-transduced CB CD34+ cells could efficiently be 
transformed along myeloid or lymphoid lineages on IL-3 and TPO-producing MSCs. 
These data indicate that these genetically engineered MSCs are sufficient to allow 
either myeloid or lymphoid transformation without the need for additional exogenous 
cytokines. Importantly, in the absence of exogenous cytokines, non-engineered MSCs 
or MS5 are not sufficient to allow in vitro transformation of MLL-AF9-transduced CB 
cells  ([27] and data not shown). We did notice that under lymphoid-permissive 
conditions the balance of MLL-AF9-induced transformation appeared to be shifted 
towards the myeloid lineage at later timepoints in comparison to when exogenous 
cytokines were added (Fig. 3C). 
Next, we assessed the ability of cyto-MSCs to differentiate in vivo. Six weeks after 
implantation, mice were sacrificed and scaffolds were analysed. No differences in the 
23 
 
ability of forming bone, fat tissue and stromal component were observed compared to 
normal MSCs.  
We then studied  the engraftment of three primary AML, B-ALL and BAL patient 
samples in our new IL3/TPO-producing cytoBM-sc model to our previous huBM-sc 
models. All three tested samples efficiently engrafted in the cytoBM-sc model, with 
latencies and immunophenotypes that did not significantly differ from what we 
previously had observed in our huBM-sc model (Fig.2 and [1]). The main differences 
were that immature CD34+ cells for the B-ALL sample were better preserved in our new 
cytoBM-sc model, and the same was true for the myeloid CD33+ immune phenotype for 
the BAL patient sample. Furthermore, engraftment of MLL-AF9-transduced CB cells 
was evaluated in the new cytoBM-sc model since it had been shown that the lineage 
fate of MLL-AF9 expressing cells can be dictated by environmental cues [15,27], and 
we compared these data to our previous huBM-sc models and IV models [27]. Injection 
of MLL-AF9-transduced CB cells into the scaffolds of cytoBM-sc models resulted in the 
development of a fatal leukemia in all the experimental animals. At sacrifice, mice 
displayed both the myelomonocytic and B-ALL immunophenotypes that are also 
observed in MLL-AF9 pediatric patients. Surprisingly, the efficiency of tumor formation 
on the injected scaffolds themselves was reduced by ~55% in the cytoBM-sc model 
compared to the previous huBM-sc model. A possible explanation for this might be that 
the local concentrations of IL-3 and TPO produced by the genetically engineered MSCs 
would be non-physiological, resulting either in the differentiation or the loss of self-
renewal properties, or potentially in the migration of leukemic cells to other mouse 
niches where the cytokine concentrations would be less high. In fact, for the first time 
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we detected complete myeloid AML clones in PB, BM, spleen and liver. Also mixed B-
ALL/AML clones were observed for the first time in spleen and liver. Although we have 
not been able to quantify the exact levels of exogenous cytokines in the different murine 
tissues, we have been able to detect human IL-3 in the liver of mice transplanted with 
cytoBM-sc by IHC. This suggests that increased levels of IL-3 might indeed underlie the 
higher frequency of myeloid and mixed clones observed in murine tissues, but further 
studies are needed to clarify these issues. As already observed in the IV NSG model 
and in the ISC huBM-sc model, also in the cytoBM-sc model CD33+-sorted myeloid 
clones failed to self-renew in secondary recipients, while B-ALL clones could readily 
engraft and give rise to secondary leukemia. This finding was somewhat unexpected 
and suggests that the presence of a modified human microenvironment that 
overexpresses IL-3 and TPO does not allow myeloid clones to self-renew properly, but 
a further fine-tuning of the levels of cytokines produced in the humanized niche might be 
required to solve these issues. The present study does clearly indicate that the 
humanized scaffold xenograft model allows for relatively simple genetic engineering of 
the bone marrow microenvironment. As such, this approach will be very useful to 
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